Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v14-FR | Version v4-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2025-02-27 | 2024-09-04 |
| Drug Identification Number | 02470780 | 02470780 |
| Brand name | AA-LANSOPRAZOLE-AMOXICILLIN-CLARITHROMYCIN | AA-LANSOPRAZOLE-AMOXICILLIN-CLARITHROMYCIN |
| Common or Proper name | AA-Lansoprazole-Amoxicillin-Clarithromycin | AA-Lansoprazole-Amoxicillin-Clarithromycin |
| Company Name | AA PHARMA INC | AA PHARMA INC |
| Ingredients | CLARITHROMYCIN AMOXICILLIN LANSOPRAZOLE | CLARITHROMYCIN AMOXICILLIN LANSOPRAZOLE |
| Strength(s) | 500MG 500MG 30MG | 500MG 500MG 30MG |
| Dosage form(s) | TABLET CAPSULE KIT CAPSULE (DELAYED RELEASE) | TABLET CAPSULE KIT CAPSULE (DELAYED RELEASE) |
| Route of administration | ORAL ORAL | ORAL ORAL |
| Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
| Additional packaging sizes | 56Bls | 56Bls |
| ATC code | A02BD | A02BD |
| ATC description | DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD) | DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD) |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | ||
| Actual start date | 2024-08-07 | 2024-08-07 |
| Estimated end date | 2025-03-10 | 2025-01-03 |
| Actual end date | 2025-02-25 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Short-dated inventory available | Short-dated inventory available |
| Health Canada comments |